Mycosis Fungoides Hospitalizations Longer for Blacks, Hispanics Mycosis Fungoides Hospitalizations Longer for Blacks, Hispanics
Results are consistent with prior studies that have found Black and Hispanic patients have earlier and more severe disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 16, 2021 Category: Cancer & Oncology Tags: Dermatology News Source Type: news

HSCT in Advanced Stage Mycosis Fungoides and Sezary Syndrome HSCT in Advanced Stage Mycosis Fungoides and Sezary Syndrome
Is HSCT potentially curative for cutaneous T-cell lymphoma?Chinese Clinical Oncology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 29, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Journal Article Source Type: news

Skin Care Guidelines for Patients With Mycosis Fungoides Skin Care Guidelines for Patients With Mycosis Fungoides
Optimal cleansers, moisturizers, and bathing habits are reviewed in these skin care guidelines for patients with cutaneous lymphoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Low-dose, Low-frequency PUVA May Be Suitable for Maintenance Therapy in Mycosis Fungoides Low-dose, Low-frequency PUVA May Be Suitable for Maintenance Therapy in Mycosis Fungoides
In patients with early-stage mycosis fungoides, treatment and maintenance therapy with low-dose, low-frequency oral psoralen - UV-A (PUVA) may extend disease-free remission, a proof-of-concept study reveals.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 27, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

What Causes Post-Inflammatory Hypopigmentation?
Discussion Hypopigmentation can be worrisome for many families because of cosmesis and the worry that “something is wrong.” The normal natural changes in skin-tone over the year due to different light exposure and wide variations within individuals is not something that many people are aware of. Post-inflammatory hypopigmentation is a common cause of hypopigmentation. Vitiligo is the most common cause of depigmentation. Vitiligo is an acquired, depigmenting disorder with typical lesions appearing as milky white macules with distinct margins that are not scaly. Hair (including eyebrows and eyelashes) can be dep...
Source: PediatricEducation.org - November 12, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma
Mogamulizumab (Poteligeo) is indicated for  relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - September 11, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

FDA Approves Poteligeo (mogamulizumab-kpkc) for Mycosis Fungoides and S ézary Syndrome
August 8, 2018 -- The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S ézary syndrome (SS) after... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 8, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Drug for Cutaneous T-Cell Lymphomas FDA Approves New Drug for Cutaneous T-Cell Lymphomas
The FDA has granted approval for mogamulizumab-kpkc for adult patients with relapsed or refractory mycosis fungoides or S é zary syndrome.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
FDA approves new drug for the treatment of adults with relapsed or refractory mycosis fungoides or S ézary syndrome after at least one prior systemic therapy (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 8, 2018 Category: American Health Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. (Source: World Pharma News)
Source: World Pharma News - August 8, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Mycosis Fungoides and Sezary Syndrome
Mycosis Fungoides and S é zary Syndrome (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 16, 2018 Category: General Medicine Source Type: news

New tool predicts deadly form of rare cancer
(Brigham and Women's Hospital) A tool to accurately determine which early-stage patients are at risk of dying from mycosis fungoides and which patients are likely to only require conventional therapy is desperately needed. Investigators from Brigham and Women's Hospital have found that next-generation, high-throughput sequencing of a specific gene (T-cell receptor beta or TCRB) is a stronger predictor of which early-stage patients will develop aggressive, progressive MF than any other established factor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2018 Category: Cancer & Oncology Source Type: news

Cutaneous T-Cell Lymphomas: Mycosis Fungoides and S ézary Syndrome
A Guide for the Practicing OncologistThird Edition CLICK HERE TO ACCESS THE WHITE PAPER (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Tags: Sponsored Resources Source Type: news

Seattle Genetics Announces FDA Approval of Adcetris (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 9, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for the treatment of adult patients with primary... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 9, 2017 Category: Drugs & Pharmacology Source Type: news

EC grants marketing authorisation for Actelion ’s Ledaga to treat MF-CTCL
The European Commission (EC) has granted marketing authorisation for 160mcg of Actelion ’s Ledaga (chlormethine gel) to treat mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 8, 2017 Category: Pharmaceuticals Source Type: news